220 related articles for article (PubMed ID: 30293218)
1. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.
Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM
Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
4. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.
Harrold LR; John A; Reed GW; Haselkorn T; Karki C; Li Y; Best J; Zlotnick S; Kremer JM; Greenberg JD
Rheumatol Ther; 2017 Dec; 4(2):405-417. PubMed ID: 28936808
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
6. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
7. Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.
Bardan I; Fagerli KM; Sexton J; Kvien TK; Bakland G; Mielnik P; Hu Y; Lien G; Flatø B; Molberg Ø; Kristianslund EK; Aga AB
J Rheumatol; 2023 Apr; 50(4):538-547. PubMed ID: 36379571
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
[TBL] [Abstract][Full Text] [Related]
11. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis.
Reed GW; Gerber RA; Shan Y; Takiya L; Dandreo KJ; Gruben D; Kremer J; Wallenstein G
Rheumatol Ther; 2019 Nov; 6(4):573-86. PubMed ID: 31707603
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
[TBL] [Abstract][Full Text] [Related]
14. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
Kremer JM; Rigby W; Singer NG; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
Arthritis Rheumatol; 2018 Aug; 70(8):1200-1208. PubMed ID: 29575803
[TBL] [Abstract][Full Text] [Related]
15. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
[TBL] [Abstract][Full Text] [Related]
16. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
Pablos JL; Navarro F; Blanco FJ; Román-Ivorra JA; Alonso A; Martín Mola E; Cantalejo M; Ercole L; Rivero N;
Clin Exp Rheumatol; 2019; 37(3):437-444. PubMed ID: 30299241
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
